NZ713046A - Therapeutic compositions for the treatment and prevention of gastrointestinal cancer - Google Patents

Therapeutic compositions for the treatment and prevention of gastrointestinal cancer

Info

Publication number
NZ713046A
NZ713046A NZ713046A NZ71304613A NZ713046A NZ 713046 A NZ713046 A NZ 713046A NZ 713046 A NZ713046 A NZ 713046A NZ 71304613 A NZ71304613 A NZ 71304613A NZ 713046 A NZ713046 A NZ 713046A
Authority
NZ
New Zealand
Prior art keywords
propolis
cyclodextrin
gastrointestinal cancer
prevention
treatment
Prior art date
Application number
NZ713046A
Inventor
Paul Kerry
Lazarova Lazarova Darina
Catchpole Owen
Original Assignee
Manuka Health New Zealand Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Manuka Health New Zealand Ltd filed Critical Manuka Health New Zealand Ltd
Priority to NZ713046A priority Critical patent/NZ713046A/en
Publication of NZ713046A publication Critical patent/NZ713046A/en

Links

Landscapes

  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

The disclosure relates to use of a synergistic therapeutic composition consisting essentially of propolis and cyclodextrin (preferably the composition is propolis – γ cyclodextrin complex or a gamma-cyclodextrin encapsulated NZ propolis) in the manufacture of a medicament for treating or preventing a gastrointestinal cancer in a subject or for inducing apoptosis of one or more neoplastic gastrointestinal cells in a subject, wherein the propolis is entirely encapsulated within the cyclodextrin.
NZ713046A 2013-04-05 2013-04-05 Therapeutic compositions for the treatment and prevention of gastrointestinal cancer NZ713046A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
NZ713046A NZ713046A (en) 2013-04-05 2013-04-05 Therapeutic compositions for the treatment and prevention of gastrointestinal cancer

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
NZ62355713 2013-04-05
NZ713046A NZ713046A (en) 2013-04-05 2013-04-05 Therapeutic compositions for the treatment and prevention of gastrointestinal cancer

Publications (1)

Publication Number Publication Date
NZ713046A true NZ713046A (en) 2017-04-28

Family

ID=58700208

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ713046A NZ713046A (en) 2013-04-05 2013-04-05 Therapeutic compositions for the treatment and prevention of gastrointestinal cancer

Country Status (1)

Country Link
NZ (1) NZ713046A (en)

Similar Documents

Publication Publication Date Title
MX2021013830A (en) Ezh2 inhibitors for treating lymphoma.
PH12016501139A1 (en) Bicyclic heterocycle compounds and their uses in therapy
NZ749218A (en) Androgen receptor modulator and uses thereof
PH12017550063A1 (en) Combination therapies for treating cancers
PH12016500868A1 (en) Compositions for use in the prevention or treatment of necrotizing enterocolitis in infants and young children
MX2016007351A (en) Combination therapy for treating cancer.
WO2013177187A3 (en) Synergistic tumor treatment with extended-pk il-2 and therapeutic agents
IL258854A (en) Compositions comprising cannabidiol and second therapeutic agents for the treatment of cancer
EA201591925A1 (en) THERAPEUTIC COMPOSITIONS AND THEIR APPLICATION
MX356755B (en) Fumigillol type compounds and methods of making and using same.
MX2017015012A (en) Topical and oral formulations comprising taurine and magnesium for the prevention and treatment of acne.
UA118474C2 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
MX2023007706A (en) Nanoparticles for use as a therapeutic vaccine.
MX2017013666A (en) Anti-fugetactic agent and immunotherapy agent combination therapy and compositions for the treatment of cancer.
MX2020002585A (en) Hdac inhibitor in combination with immune checkpoint modulator for cancer therapy.
NZ713046A (en) Therapeutic compositions for the treatment and prevention of gastrointestinal cancer
PH12014501044A1 (en) Methods for improved wound closure employing olivamine and human umbilical vien endothelial cells
MX2021001081A (en) Combination therapy for treating cancer.
MX2018015240A (en) Compositions comprising timolol and their use in the treatment of rosacea by topical administration.
MX2017013668A (en) Anti-fugetactic agent and anti-cancer agent combination therapy and compositions for the treatment of cancer.
MX2017011838A (en) Compositions and methods for treating hepatocellular carcinoma.
MX2018003308A (en) Localized delivery of anti-fugetactic agent for treatment of cancer.
GB2546703A (en) Compounds
RU2012158011A (en) METHOD AND COMPOSITION FOR TREATMENT OF CANCER
NZ629711A (en) Anti-inflammatory compositions, methods and uses thereof

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2019 BY AJ PARK

Effective date: 20180326

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2020 BY AJ PARK

Effective date: 20190325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2021 BY AJ PARK

Effective date: 20200326

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2022 BY AJ PARK

Effective date: 20210325

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2023 BY AJ PARK

Effective date: 20220302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 07 APR 2024 BY AJ PARK

Effective date: 20230324